Psoriasis is one of the most visible chronic diseases in medicine and one of the most misunderstood. Around 7.5 million American adults live with it, and most have had to explain to a stranger that the patches on their skin cannot be caught.
Psoriasis is also more than skin: the immune signaling that thickens a plaque on your elbow is measurable in your joints, arteries and metabolism, which is why a dermatology visit increasingly comes with a lab requisition.
What is psoriasis?
Psoriasis is a chronic, immune-mediated inflammatory disease in which overactive immune signaling drives skin cells to multiply far too fast. Healthy keratinocytes, the cells of the outer skin layer, take roughly a month to reach the surface and shed; in psoriatic skin that collapses to a few days, so cells pile up as a raised, scaly plaque.
Psoriasis is not contagious. You cannot catch it by touching a plaque, sharing a towel or swimming in the same pool. There is no bacterium, virus or fungus to transmit, and no amount of contact gives psoriasis to someone without the underlying immune predisposition.
Genetic susceptibility, strongest at the HLA-C*06:02 locus, combines with a trigger to activate the IL-23/Th17 axis: dendritic cells release interleukin-23, which sustains T helper 17 cells, and those release interleukin-17 and tumor necrosis factor, inflaming skin and driving cell division. Every targeted drug interrupts one step in that loop.
Types of psoriasis
Psoriasis is a family of presentations, and one form can convert into another after stress or a medication change.
| Type | What it looks like | Typical sites |
|---|---|---|
| Plaque psoriasis | Raised, sharply bordered patches with thick scale; 80 to 90 percent of cases | Elbows, knees, lower back, scalp |
| Guttate psoriasis | Shower of small drop-shaped spots, often weeks after strep throat | Trunk, upper arms, thighs |
| Inverse psoriasis | Smooth, shiny patches with little scale, as moisture prevents it forming | Armpits, groin, under breasts |
| Pustular psoriasis | Sterile white pustules on inflamed skin, localized or generalized | Palms and soles, or widespread |
| Erythrodermic psoriasis | Widespread inflammation and peeling with fever and fluid loss | Nearly the whole skin surface |
| Nail psoriasis | Pitting, oil-drop discoloration, crumbling, nail-bed separation | Fingernails and toenails |
| Scalp psoriasis | Thick adherent scale past the hairline; temporary shedding possible | Scalp, behind ears, nape of neck |
Symptoms and how psoriasis looks on different skin tones
The classic lesion is a raised, sharply bordered plaque with thick scale, often itchy, prone to cracking, and frequently mirrored on both elbows or knees. The Koebner phenomenon means new plaques erupt exactly where skin was injured. Itch is underrated, and it is one reason clinicians must first exclude eczema, a separate group of itch-dominant inflammatory skin conditions.
How psoriasis appears on brown and Black skin
Textbooks have historically illustrated psoriasis on white skin, and patients with skin of color face longer diagnostic delays and lower referral rates as a result. On darker skin, plaques rarely look red. They appear violet, deep purple, grey-brown or almost black, with greyish rather than silvery scale. Because the inflammation is harder to see, severity is routinely underestimated, which affects who is offered systemic treatment.
Post-inflammatory pigment change is the second issue and often the more distressing one. After a plaque clears, the skin beneath is often left darker or lighter than the surrounding area for months or years. These marks are not scars and usually fade, but treating plaques promptly limits them.
The forms that are medical emergencies
Two presentations need immediate care, not a routine appointment. Erythrodermic psoriasis, in which inflammation and peeling engulf most of the body surface, destroys the skin’s ability to regulate temperature and retain fluid, risking dehydration, heart strain and infection. Generalized pustular psoriasis, a sudden eruption of widespread sterile pustules with fever and profound fatigue, carries similar risk. Both can follow abrupt corticosteroid withdrawal, and both belong in an emergency room.
Causes and triggers
Psoriasis is a gene-environment disease. About a third of patients have an affected first-degree relative and over 80 susceptibility loci are known, but genes alone are not enough: something must switch the loop on.
- Infection, especially strep throat, the classic precipitant of guttate psoriasis.
- Skin injury of any kind: cuts, bites, vaccinations, tattoos and sunburn.
- Psychological stress, which worsens disease in many patients.
- Certain drugs, including lithium, beta blockers, antimalarials and corticosteroid withdrawal.
- Smoking, heavy alcohol use and obesity, all of which raise severity and blunt treatment response.
- Cold, dry weather, which explains the winter worsening most patients describe.
Psoriatic arthritis: the joint connection
Up to about one in three people with psoriasis develop psoriatic arthritis, an inflammatory arthritis attacking joints, tendon insertions and the spine. Skin disease usually comes first, often by a decade, giving dermatology a chance to catch it early. That matters because joint erosion does not reverse.
Warning signs are distinctive: morning stiffness lasting over 30 minutes, swelling of a whole finger or toe into a sausage shape, pain where tendons anchor into bone, and back pain that eases with movement. Nail pitting and nail-bed separation are red flags too.
No single blood test confirms it. Laboratory work instead excludes look-alikes, since most people with psoriatic arthritis test negative for the antibodies that characterize rheumatoid arthritis, a symmetric autoimmune joint disease. When the spine is involved, the pattern closely resembles ankylosing spondylitis, an inflammatory arthritis of the spine and pelvis.
Beyond the skin: what else psoriasis raises the risk of
Chronic inflammation does not stay in the skin, which is why this diagnosis deserves a whole-body workup. Circulating cytokines damage blood vessel linings and accelerate atherosclerosis, the fatty plaque buildup that narrows arteries, raising heart attack and stroke rates independent of smoking and weight.
Metabolic syndrome, type 2 diabetes, fatty liver disease and abnormal lipids cluster with psoriasis, and severity tends to track together. Inflammatory bowel disease, uveitis and chronic kidney disease appear more often than expected, and depression and anxiety are roughly twice as common as in the general population, with inflammatory signaling contributing rather than appearance alone. None of this warrants alarm; it warrants surveillance, because these risks are cheap to screen.
How psoriasis is diagnosed
Psoriasis is usually a clinical diagnosis. A dermatologist examines skin, scalp and nails and asks about family history; distribution and nail pitting are powerful clues. A biopsy is taken occasionally, when the differential includes cutaneous lymphoma, tinea or a drug eruption. Severity is graded with body surface area and the Psoriasis Area and Severity Index.
The blood tests that matter
No blood test diagnoses psoriasis. Laboratory work serves two other purposes: screening for the comorbidities above, and monitoring systemic treatment safety. Most dermatologists check an LDL cholesterol result that reflects cardiovascular risk within a lipid panel, and screen for a fasting glucose value that flags emerging insulin resistance or an HbA1c. Liver enzymes matter because fatty liver is common and several systemic drugs are cleared hepatically. To gauge inflammation, clinicians may order a C-reactive protein test that quantifies systemic inflammatory activity, and the same panel often includes an erythrocyte sedimentation rate that tracks inflammation over longer intervals. Before any biologic or targeted oral therapy, screening for latent tuberculosis and hepatitis B and C is standard.
Treatment options
Treatment is chosen by severity, sites involved and comorbidities. Nothing here is a recommendation to start, stop or change a medication.
Topicals are first line for limited disease. Corticosteroids act quickly and are monitored visually for skin thinning with prolonged use of potent formulations. Vitamin D analogues normalize cell turnover and are often paired with a steroid. Newer non-steroidal creams include a phosphodiesterase-4 inhibitor and an aryl hydrocarbon receptor agonist.
Phototherapy suits widespread thin plaques. Narrowband UVB in clinic two or three times weekly is standard; PUVA adds a psoralen sensitizer for resistant disease. Monitoring is dermatologic, not laboratory-based: cumulative dose is tracked, skin exams screen for photodamage and skin cancer, and eye protection is mandatory with psoralen.
Among conventional systemics, methotrexate needs periodic blood counts, liver enzymes and kidney function, plus hepatitis screening and strict pregnancy avoidance. Cyclosporine works fast but demands blood pressure, creatinine and electrolyte monitoring in short courses. Acitretin requires triglyceride and liver checks and is contraindicated in pregnancy. Apremilast needs no routine bloodwork but warrants attention to weight and mood. Deucravacitinib, an oral tyrosine kinase 2 inhibitor acting upstream of interleukin-23, involves tuberculosis screening plus liver and lipid checks.
Biologics are injected antibodies neutralizing one cytokine each. Tumor necrosis factor inhibitors carry the heaviest monitoring: tuberculosis screening before and during treatment, hepatitis serology, and vigilance for demyelinating disease and heart failure. Interleukin-12/23 inhibitors block a shared subunit and dose infrequently. Interleukin-17 inhibitors clear skin rapidly but require attention to thrush and caution in inflammatory bowel disease. Interleukin-23 p19 inhibitors act at the top of the pathway with the lightest monitoring, though tuberculosis screening still applies.
Daily management and skin care
Thick emollients applied to damp skin after bathing reduce scale, cracking and itch; ointments outperform lotions. Short lukewarm showers preserve barrier lipids; long hot ones strip them. Gentle descaling with salicylic acid or urea helps topical drugs reach thick plaques, especially on the scalp. Picking invites new Koebner lesions.
Weight management improves severity and treatment response in people with obesity, and smoking cessation is among the highest-value changes available. Because stress is such a consistent trigger, therapy, mindfulness and exercise deserve to be taken seriously.
Living with psoriasis: outlook
Psoriasis is a lifelong condition without a cure, and honest framing matters more than optimism. What has changed is what control looks like: twenty years ago a 75 percent improvement was an ambitious trial endpoint, while today clear or almost clear skin is realistic for many.
The disease waxes and wanes, with spontaneous remissions lasting months or years and flares following infection, stress or a medication change. Life expectancy is largely normal when comorbidities are managed, the strongest argument for routine cardiometabolic surveillance.
Latest scientific advances
A phase 3 trial in the New England Journal of Medicine tested icotrokinra, an oral peptide blocking the interleukin-23 receptor, the same target as injected biologics but taken as a daily tablet. ICONIC-LEAD randomized 684 people aged 12 and over with moderate-to-severe plaque psoriasis: 456 to the drug, 228 to placebo. At week 16, 65 percent on icotrokinra had clear or almost clear skin versus 8 percent on placebo, and 50 percent reached a 90 percent reduction in severity versus 4 percent. Adverse events affected 49 percent of each group (Bissonnette et al., 2025). What this means for you: a tablet hitting this target may widen access for people who cannot use needles.
The MEDIPSO trial in JAMA Dermatology asked whether diet alone shifts psoriasis severity. Thirty-eight adults with mild to moderate disease on stable topical treatment were randomized to a 16-week dietitian-guided Mediterranean diet with extra virgin olive oil, or to standard low-fat advice. Severity scores improved by 3.4 points in the diet group and did not change in controls, a difference of -3.4 points (95 percent confidence interval -4.8 to -2.0). Nine of 19 diet participants, 47.4 percent, reached a 75 percent improvement, against none in controls (Perez-Bootello et al., 2025). What this means for you: small and single-center, but the first randomized evidence that an eating pattern measurably improves plaques.
A network meta-analysis in Dermatology and Therapy compared every biologic approved for moderate-to-severe plaque psoriasis, a method that ranks drugs never tested head-to-head by linking shared comparisons. The authors screened 7,418 publications, identified 124 randomized trials, and analyzed 103 of them across 12 biologics at week 28. All beat placebo on skin clearance and quality of life, the interleukin-23 inhibitors tildrakizumab, risankizumab and guselkumab performed comparably, and none raised serious adverse event risk (Lebwohl et al., 2025). What this means for you: when options look alike on efficacy, dosing interval and coverage drive the decision.
Myths and facts
- Myth: psoriasis is contagious. Fact: no infectious agent is involved, so it cannot pass by touch, towels or pools.
- Myth: it is just dry skin. Fact: moisturizer eases symptoms but not the immune inflammation.
- Myth: it only affects skin. Fact: up to a third develop psoriatic arthritis, and cardiometabolic risks rise.
- Myth: plaques always look red. Fact: on brown and Black skin they commonly appear violet, grey or dark brown.
- Myth: oral steroids are a good fix. Fact: stopping them can trigger severe rebound, including pustular flares.
Glossary
| Term | Meaning |
|---|---|
| Plaque | A raised, well-defined area of thickened skin, usually scaly. |
| Keratinocyte | The main cell of the outer skin layer, multiplying far too fast in psoriasis. |
| Koebner phenomenon | New lesions appearing at the exact site of a skin injury. |
| PASI | Psoriasis Area and Severity Index, scoring redness, thickness and area. |
| Dactylitis | Swelling of a whole finger or toe into a sausage shape. |
| Post-inflammatory pigment change | Darkening or lightening left after a plaque heals. |
| Enthesitis | Inflammation where a tendon attaches to bone, such as the heel. |
| Biologic | An injected antibody that neutralizes one specific immune signal. |
| Interleukin-23 | A messenger protein sustaining the inflammatory loop behind psoriasis. |
Frequently asked questions
Is psoriasis contagious?
No. Psoriasis cannot be passed to another person under any circumstances. No bacterium, virus or fungus causes it, so there is nothing to transmit through touch, shared towels, bedding, gym equipment, pools or sexual contact. What runs in families is genetic susceptibility, not the disease itself, and even that needs a trigger to become active. If someone avoids contact because of your skin, that is a misunderstanding worth correcting.
What causes psoriasis?
Psoriasis results from an inherited tendency toward overactive immune signaling switched on by an environmental trigger. Over 80 genetic loci contribute, the strongest being HLA-C*06:02. Once activated, dendritic cells release interleukin-23, which sustains T helper 17 cells producing interleukin-17 and tumor necrosis factor; those signals inflame skin and accelerate cell turnover. Common triggers include strep throat, skin injury, stress, smoking, obesity and corticosteroid withdrawal.
Is psoriasis an autoimmune disease?
It is usually classified as immune-mediated rather than strictly autoimmune. Classic autoimmune diseases involve antibodies attacking an identified self-antigen, and no such antibody defines psoriasis; instead an overactive T-cell pathway drives the inflammation. The distinction is largely academic: psoriasis behaves like an autoimmune condition, clusters with inflammatory bowel disease and uveitis, and responds to drugs that dampen specific immune signals.
What does psoriasis look like?
The commonest form is a raised, sharply bordered plaque topped with thick scale, often on elbows, knees, scalp or lower back, and frequently symmetric. Appearance varies with skin tone: on lighter skin plaques look pink or red with silvery scale, while on brown and Black skin they typically appear violet, grey or dark brown with greyish scale. Other forms differ, including guttate spots and pitted nails.
How do you get rid of psoriasis?
There is no cure, but clearance of visible disease is now realistic for many people. Treatment escalates by severity: topical steroids, vitamin D analogues and newer non-steroidal creams for limited disease; narrowband UVB phototherapy for widespread thin plaques; and oral systemics or injected biologics targeting tumor necrosis factor, interleukin-17 or interleukin-23 for moderate-to-severe disease. The right route depends on severity, comorbidities and monitoring needs.
Sources
- NIAMS — Psoriasis — National Institutes of Health, 2023 — niams.nih.gov
- MedlinePlus — Psoriasis — U.S. National Library of Medicine, 2024 — medlineplus.gov
- American Academy of Dermatology — Psoriasis: Overview — AAD, 2024 — aad.org
- Mayo Clinic — Psoriasis: Symptoms and Causes — Mayo Clinic, 2025 — mayoclinic.org
- National Psoriasis Foundation — About Psoriasis — NPF, 2025 — psoriasis.org
- Bissonnette R et al. — Oral Icotrokinra for Plaque Psoriasis — New England Journal of Medicine, 2025 — doi.org
- Perez-Bootello J et al. — Mediterranean Diet and Patients With Psoriasis — JAMA Dermatology, 2025 — doi.org
- Lebwohl MG et al. — Biologics for Moderate-to-Severe Plaque Psoriasis — Dermatology and Therapy, 2025 — doi.org
Further reading
- Because insulin resistance clusters with psoriasis, it helps to understand diabetes, its warning signs and its management.
- If a rash comes with fatigue and joint pain, read our guide covering lupus, an autoimmune disease that mimics other rashes.
- People on phototherapy often check vitamin D, its blood levels and what they mean.
- To go deeper on low-grade inflammation, read our article on hs-CRP, the high-sensitivity marker of silent inflammation.
Understand your lab results with BloodSense
Living with psoriasis means living with numbers as well as plaques: lipid panels, glucose or HbA1c, liver enzymes, inflammatory markers and the safety bloods that come with systemic therapy. Those results arrive as columns of figures with little explanation, so it is hard to know what has drifted.
BloodSense reads your lab report and explains each marker in plain language, showing how your values sit against reference ranges and how they have moved over time. It is educational rather than a substitute for your dermatologist, but it makes that conversation easier.
